Co-locates with technology developers Factor Bioscience and Novellus Therapeutics

June 02, 2021 08:00 ET | Source: Brooklyn ImmunoTherapeutics

BROOKLYN, N.Y., June 02, 2021 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced it has established a research and development center in Cambridge, Massachusetts, to pursue its mRNA-based gene editing and cellular therapies. The company has co-located with Factor Bioscience Limited (“Factor”) and Novellus Therapeutics Limited (“Novellus”), from which Brooklyn has acquired an exclusive worldwide license to develop and commercialize certain cell-based therapies to treat cancer and rare blood disorders, including sickle cell disease, based on the patented technology and know-how of Factor and Novellus.

“Our new R&D facility will provide us with the ability to advance our research and development efforts. We believe co-locating with Factor and Novellus will promote our capability to leverage our collaboration and further our objectives in developing a diversified portfolio of new, advanced therapeutics,” said Howard J. Federoff, M.D., Ph.D., Brooklyn’s Chief Executive Officer and President. “Recent presentations by Factor and Novellus at the American Society of Gene & Cell Therapy conference have reinforced our conviction that our development pathways can be broadly applicable to real world disease indications for which no effective therapies currently exist.”